Harnessing Apoptosis in AML

Clin Lymphoma Myeloma Leuk. 2021 Sep 4:S2152-2650(21)02018-8. doi: 10.1016/j.clml.2021.08.015. Online ahead of print.ABSTRACTThe treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules. While agents such as FLT3 inhibitors and IDH inhibitors are restricted for patients with specific mutations, the selective BCL-2 inhibitor venetoclax combined with a hypomethylating agent or low-dose cytarabine was approved after demonstrating frontline efficacy across a molecularly heterogenous group of patients. Currently, venetoclax is being investigated in combination with multiple other therapies as the role of the intrinsic apoptotic pathway in acute myeloid leukemia continues to be explored.PMID:34602371 | DOI:10.1016/j.clml.2021.08.015

Source: Clinical Lymphoma and Myeloma - October 4, 2021 Category: Cancer & Oncology Authors: Kapil Saxena Courtney DiNardo Naval Daver Marina Konopleva Source Type: research